LAVAL, Quebec, March 9, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and R&O Pharmacy, LLC (R&O) today announced that they have jointly requested the Court to dismiss the litigation between them pursuant to a confidential settlement agreement that resolves all claims between them. While the terms of the settlement are confidential, the resolution includes a payment by R&O to Valeant. As noted at the onset of the matter, Valeant firmly believes it acted appropriately and refutes any suggestion of wrongdoing.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
Elif McDonald
905-695-7607
elif.mcdonald@valeant.com
Media:
Renee E. Soto/Meghan Gavigan
Sard Verbinnen & Co.
212-687-8080
rsoto@sardverb.com / mgavigan@sardverb.com
Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-and-ro-pharmacy-end-litigation-300233733.html
SOURCE Valeant Pharmaceuticals International, Inc.
